# A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs

> **NCT00002442** · PHASE2 · COMPLETED · sponsor: **Glaxo Wellcome**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Indinavir sulfate
- **DRUG:** Nelfinavir mesylate
- **DRUG:** Lamivudine
- **DRUG:** Stavudine

## Key facts

- **NCT ID:** NCT00002442
- **Lead sponsor:** Glaxo Wellcome
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002442, "A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00002442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*